MiPLA

Methylisopropyllysergamide

Lamide

Psychoactive Class

Chemical Class

MiPLA is a lesser-known psychedelic of the lysergamide class and a structural isomer of LSD.¹ First discovered by Albert Hofmann during the original structure-activity research for LSD, it was later studied in greater detail by David E. Nichols at Purdue University.² MiPLA is reported to produce effects similar to LSD but with a shorter duration, subtler visuals, a less introspective headspace, and a generally less anxiety-provoking profile. It is approximately two- to threefold less potent than LSD.²

Dosage & Duration

Dosage

Threshold~50 μg

Light50-150 μg

Moderate150-200 μg

Strong200-300 μg

Heavy300+ μg

Duration

Onset20-40 minutes

Come Up45-90 minutes

Peak1-2 hours

Offset1-2 hours

Total4-6 hours

Subjective Effects

MiPLA produces a classic lysergamide psychedelic experience that closely resembles LSD in overall character, though it is generally reported as milder and shorter-lasting at comparable doses, with human potency estimated at roughly one third to one half that of LSD. The experience is often described as gentle and manageable, following a familiar arc of gradual onset, a plateau of moderate psychedelic alteration, and a comparatively smooth return to baseline.

Physical

The body load is generally mild, with light stimulation and few pronounced physical effects reported.

Pupil dilation

Cognitive

The headspace is commonly described as relatively light and lucid, with a mild euphoric tone and less cognitive force or intensity than LSD.

Time distortion

Visual

Visual effects are present but typically subtler than those of LSD, scaling with dose in the usual lysergamide fashion.

Color enhancement

Distortions

Drifting Tracers

Reagent Testing

Loading reagent data

Expected colorimetric results are being prepared.

Pharmacology

Pharmacodynamics

MiPLA principally acts as an agonist at the serotonin 5-HT2A receptor, which is considered its primary mechanism for producing psychedelic effects. One source characterizes it specifically as a partial agonist at this site. It also interacts with dopamine D1 and D2 receptors, and more broadly shares a similar monoamine receptor binding profile with LSD across serotonin, dopamine, and norepinephrine systems.² MiPLA has approximately 33 to 50% of the potency of LSD and fully substitutes for LSD in rodent drug discrimination assays.²¹

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

CannabisLithiumStimulantsTramadol

TripSit

Tolerance

Full Tolerance

Tolerance to the effects of MiPLA develops almost immediately after ingestion.

Baseline Reset

Approximately 14 days to return to baseline tolerance in the absence of further consumption.

Half Tolerance

Approximately 5-7 days for tolerance to reduce to half in the absence of further consumption.

Cross Tolerance

Serotonergic psychedelics (due to shared activity at the 5-HT2A receptor)

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

Like other serotonergic psychedelics, MiPLA is believed to have a low potential for abuse and psychological dependence, owing to its structural and pharmacological similarities with LSD.³⁴ These claims are preliminary and based on anecdotal rather than clinical evidence.

Physical

Extremely Low

MiPLA is believed to have a low potential for dependence based on its structural and pharmacological similarities with LSD and other serotonergic psychedelics. No physical dependence has been documented.³

Psychosis Risk

MiPLA may trigger psychiatric difficulties in people with pre-existing psychiatric conditions. People with their own history of mental illness, or a family history of it, are generally advised to avoid this substance. Delusions and other adverse psychological reactions are more likely at higher doses.

Seizure Risk

The possibility of seizures is extrapolated from rarely reported cases with LSD. Seizures are thought to mainly be a risk in those who are genetically predisposed, particularly when accompanied by physically taxing conditions such as dehydration, fatigue, or undernourishment.⁵

History & Culture

MiPLA was originally synthesized by Albert Hofmann at Sandoz Laboratories as part of the foundational structure-activity relationship research into LSD. Eli Lilly and Company subsequently filed a patent for the compound in 1956, with formal publication following in 1961.…

Legality

By Country

United StatesUnscheduled

Not specifically scheduled under the Controlled Substances Act. May be prosecuted under the Federal Analogue Act as a structural analogue of LSD when intended for human consumption.

GermanyNpSG controlled

Regulated under the Neue Psychoaktive Substanzen Gesetz (New Psychoactive Substances Act) since July 18, 2019.⁷ Production, import with intent to distribute, administration to others, and commercial trading are prohibited offenses.⁸ Possession is technically illegal but does not carry penalties.

AustriaUnscheduled (grey area)

Not specifically prohibited but may fall under the Neue-Psychoaktive-Substanzen-Gesetz (NPSG) due to structural similarity to LSD.

SwitzerlandControlled (Verzeichnis E)

Classified as a controlled substance under Verzeichnis E point 263 as a defined derivative of lysergic acid. Exempted when used for legitimate scientific or industrial purposes.

References

Source Pages

Citations

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the MiPLA article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

MiPLA

Methylisopropyllysergamide

Lamide

Psychoactive Class

Psychedelic

Chemical Class

Lysergamide